A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder

Journal of Clinical Psychopharmacology

Volumn 31, Issue 6, 2011, Pages 763-768

  Diniz, Juliana Belo ^a   Shavitt, Roseli Gedanke ^a   Fossaluza, Victor ^a   Koran, Lorrin ^b   Pereira, Carlos Alberto De Bragança ^a   Miguel, Euripedes Constantino ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antidepressant agents; antipsychotic agents; clinical trial; combined therapy; obsessive compulsive disorder

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; PLACEBO; QUETIAPINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEDATION; SHORT FORM 36; SIDE EFFECT; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; SYNCOPE; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CLOMIPRAMINE; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80755135530     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182367aee     Document Type: Article

References (56)

1. Angst J, Gamma A, Endrass J, et al. Obsessive-compulsive severity spectrum in the community: prevalence, comorbidity, and course. Eur Arch Psychiatry Clin Neurosci. 2004;254(3):156-164. (Pubitemid 39304465)
2. Rufer M, Hand I, Alsleben H, et al. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):121-128. (Pubitemid 40575663)
3. Gururaj G, Math S, Reddy J, et al. Family burden, quality of life and disability in obsessive compulsive disorder: an Indian perspective. J Postgrad Med. 2008;54(2):91-97. (Pubitemid 351724190)
4. Leon A, Portera L, Weissman M. The social costs of anxiety disorders. Br J Psychiatry Suppl. 1995;(27):19-22.
5. Koran L. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23(3):509-517. (Pubitemid 30666503)
6. Fineberg N, Craig K. Pharmacological treatment for obsessive-compulsive disorder. Psychiatry. 2007;6(6):234-239. (Pubitemid 46850823)
7. Marazziti D, Consoli G. Treatment strategies for obsessive-compulsive disorder. Exp Opin Pharmacother. 2010;11(3):331-343.
8. Rosa-Alcázar A, Sánchez-Meca J, Gómez-Conesa A, et al. Psychological treatment of obsessive-compulsive disorder: a meta-analysis. Clin Psychol Rev. 2008;28(8):1310-1325.
9. Walsh K, McDougle C. Pharmacological augmentation strategies for treatment-resistant obsessive-compulsive disorder. Exp Opin Pharmacother. 2004;5(10):2059-2067. (Pubitemid 39406108)
10. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disordersVfirst revision. World J Biol Psychiatry. 2008;9(4):248-312.
11. Greist J, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr. 2003;8(8 suppl 1):7-16. (Pubitemid 38419777)
12. Bloch M, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-632. (Pubitemid 43989810)
13. Matsunaga H, Nagata T, Hayashida K, et al. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J Clin Psychiatry. 2009;70(6):863-868.
14. Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(1):CD006625.
15. Carey P, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry. 2005;5:5.
16. Denys D, de Geus F, van Megen H, et al. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(8):1040-1048.
17. Fineberg N, Sivakumaran T, Roberts A, et al. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005;20(4):223-226. (Pubitemid 40896377)
18. Vulink N, Denys D, Fluitman S, et al. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry. 2009;70(7):1001-1008.
19. Kordon A, Wahl K, Koch N, et al. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2008;28(5):550-554.
20. Fineberg N, Stein D, Premkumar P, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol. 2006;21(6):337-343. (Pubitemid 44498275)
21. Reddy Y, Alur A, Manjunath S, et al. Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(3):267-272.
22. Ross S, Fallon B, Petkova E, et al. Long-term follow-up study of patients with refractory obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2008;20(4):450-457.
23. Diniz J, Shavitt R, Pereira C, et al. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J Psychopharmacol. 2010;24(3):297-307.
24. International Conference on Harmonisation. Guideline for Good Clinical PracticesVICH Harmonised Tripartite Guideline. 1996. Available at: http://www.ich.org/cache/compo/276-254-1.html. Acessed January 20, 2011.
25. Meyer J, Wilson A, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161(5):826-835. (Pubitemid 38625335)
26. Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30(7):1206-1227.
27. Crewe H, Lennard M, Tucker G, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34(3):262-265.
28. Denys D, Fineberg N, Carey P, et al. Quetiapine addition in obsessive-compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiatry. 2007;61(3):412-414. (Pubitemid 46108696)
29. Goodman W, Price L, Rasmussen S, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. (Pubitemid 19278229)
30. Goodman W, Price L, Rasmussen S, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry. 1989;46(11):1012-1016. (Pubitemid 19278230)
31. Guy W. Clinical Global Impression. In: ECDEUAssessment Manual for Psychopharmacology, Revised. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research branch. Rockville, MD: National Institutes of Mental Health; 1976:218-221.
32. Beck A, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7(0):151-169.
33. Beck A, Epstein N, Brown G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893-897. (Pubitemid 19008360)
34. Weissman M, Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry. 1976;33(9):1111-1115.
35. Ware JJ, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.
36. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002.
37. First MB. Structured Clinical Interview for DSM-IV-TR Impulse Control Disroders Not Otherwise Specified (SCID-TCIm). New York: Biometrics Research, New York State Psychiatric Institute; 2004.
38. Eisen J, Phillips K, Baer L, et al. The Brown Assessment of Beliefs Scale: reliability and validity. Am J Psychiatry. 1998;155(1):102-108. (Pubitemid 28037556)
39. Fossaluza V, Diniz J, Pereira BB, et al. Sequential allocation to balance prognostic factors in a psychiatric clinical trial. Clinics (Sao Paulo). 2009;64(6):511-518.
40. Singer JM, Poleto FZ, Rosa P. Parametric and nonparametric analyses of repeated ordinal categorical data. Biometr J. 2004;46(4):460-473. (Pubitemid 41449106)
41. Pallanti S, Quercioli L, Paiva R, et al. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry. 1999;14(2):101-106.
42. Browne M, Horn E, Jones T. The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder. Can J Psychiatry. 1993;38(4):242-243. (Pubitemid 23203063)
43. Marazziti D, Golia F, Consoli G, et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr. 2008;13(11):971-976.
44. Figueroa Y, Rosenberg D, Birmaher B, et al. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol. 1998;8(1):61-67. (Pubitemid 28270779)
45. Ravizza L, Barzega G, Bellino S, et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull. 1996;32(4):677-682. (Pubitemid 26428273)
46. Sternbach H. Fluoxetine-clomipramine interaction. J Clin Psychiatry. 1995;56(4):171-172.
47. Amsterdam J, Garća-España F, Rosenzweig M. Clomipramine augmentation in treatment-resistant depression. Depress Anxiety. 1997;5(2):84-90. (Pubitemid 128769717)
48. Koskinen H, Martikainen J, Maljanen T. Antipsychotics and antidepressants: an analysis of cost growth in Finland from 1999 to 2005. Clin Ther. 2009;(31 pt 1):1469-1477.
49. Gefvert O, Lundberg T, Wieselgren I, et al. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001;11(2):105-110. (Pubitemid 32335553)
50. Busatto G, Pilowsky L, Ell P, et al. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone. Br J Psychiatry. 1993;163:833-834. (Pubitemid 23352987)
51. Yasuno F, Suhara T, Okubo Y, et al. Dose relationship of limbic-cortical D2-dopamine receptor occupancy with risperidone. Psychopharmacology (Berl). 2001;154(1):112-114. (Pubitemid 32186522)
52. Bloch M, McGuire J, Landeros-Weisenberger A, et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15(8):850-855.
53. Blier P, de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry. 1998;44(5):313-323. (Pubitemid 28432642)
54. Rasmussen S, Hackett E, DuBoff E, et al. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997;12(6):309-316. (Pubitemid 28133228)
55. Koran L, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry. 2002;159(1):88-95. (Pubitemid 41070732)
56. Liebowitz M, Lam R, Lepola U, et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27(10):964-976.